Physician profile
Paul Lerner
NPI 1861411456
$5,697.37
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $839 · 2021: $1,360 · 2022: $1,281 · 2023: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $637.74 | 2019-2023 | Austedo Xr |
| Abbvie INC. | $557.14 | 2021-2023 | |
| Biogen, INC. | $402.62 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $334.83 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $311.74 | 2022 | |
| Allergan, INC. | $305.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $300.79 | 2019-2021 | |
| Corium, LLC | $284.87 | 2022-2023 | Adlarity |
| Boston Scientific Corporation | $266.54 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $243.24 | 2020-2021 | |
| Lilly USA, LLC | $228.56 | 2019-2022 | |
| Amgen INC. | $221.32 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $194.38 | 2020-2021 | |
| Genzyme Corporation | $159.88 | 2021-2022 | |
| Pfizer INC. | $140.01 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $123.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $108.16 | 2019 | |
| Lundbeck LLC | $102.77 | 2019-2021 | |
| Alkermes, INC. | $89.46 | 2019 | |
| Eisai INC. | $86.90 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $86.59 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $78.93 | 2019-2022 | |
| Assertio Therapeutics, INC. | $78.76 | 2019-2020 | |
| Sk Life Science, INC. | $68.04 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.26 | 2021 | |
| Acorda Therapeutics, INC | $40.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.78 | 2023 | Amvuttra |
| Currax Pharmaceuticals LLC | $23.27 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $23.19 | 2020 | |
| Kyowa Kirin, INC. | $22.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.80 | 2019 | |
| Neurelis, INC. | $20.95 | 2020 | |
| Adamas Pharmaceuticals, INC. | $20.88 | 2019 | |
| Medtronic, INC. | $19.47 | 2021 | |
| Ucb, INC. | $14.27 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.